Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HORIZON: GSK4532990 in Adults With NASH and Advanced Fibrosis
jRCT2041220100Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Jan 2023
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
01
Overview
Phase 2, randomised, double-blind trial of GSK4532990 in metabolic dysfunction-associated steatohepatitis (MASH) (3 arms), sponsored by GSK. Primary endpoints: Histologic fibrosis improvement without NASH worsening at Week 52 (F3 cohort) and NASH resolution without fibrosis worsening at Week 52 (F3 cohort). Started Jan 2023; status: active, not recruiting.
02
Drugs
GSK4532990
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on jRCT2041220100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220100.